A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Canakinumab (Primary) ; Capmatinib (Primary) ; LAG 525 (Primary) ; Spartalizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PLATforM
- Sponsors Novartis Pharmaceuticals
- 05 Jul 2018 Planned number of patients changed from 160 to 135.
- 05 Jul 2018 Planned End Date changed from 14 Jul 2021 to 30 Aug 2021.
- 05 Jul 2018 Planned primary completion date changed from 12 Nov 2020 to 29 Dec 2020.